Back to School: How biopharma can reboot drug development. Access exclusive analysis here

La Jolla down on Riquent news

LJPC was down $1.67 (61%) to $1.09 on

Read the full 87 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE